Nastech Pharmaceutical Company Inc.
Development program initiated for intranasal formulation of rapid-acting insulin
Published in Biotech Law Weekly, November 18th, 2005
The formulation is being developed using Nastech's formulation science expertise and high-throughput human tissue culture screening process, a proprietary system for developing large molecule therapeutics that are delivered across the nasal mucosa. Nastech's human tissue culture studies have been demonstrated to have a high correlation with in vivo clinical drug bioavailability.
Proteins and peptides such as insulin are typically delivered by injection because they cannot be delivered orally...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
Source: Biotech Law Weekly (2005-11-18)
More Articles from Biotech Law Weekly
- Boston Medical Center
Growth hormone is illegal for off-label anti-aging use - Dartmouth Medical School
Health cost disparity is partly due to physician behavior - EduNeering
Knowledge solutions company rolls out Medicare Part D nine-course curriculum - EntreMed, Inc.
Patents for rheumatoid arthritis compound granted by European Patent Office - IMS Health
Global pharmaceutical market set to grow 6-7% in 2006; U.S. demand increasing - Intranasal Therapeutics, Inc.
Patent request filed for THC nasal spray to control nausea and vomiting - More from this issue of Biotech Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
